Research
Molecular
ALOXE3 is activated during fasting and enhances insulin sensitivity via hepatic PPARγ.
Targeting ALOXE3 may be a viable strategy for improving insulin sensitivity in metabolic diseases.
StrongSupportsmedium confidence
Here, we demonstrate the lipoxygenase, ALOXE3, is a novel effector of the hepatic fasting response.
Why this rating
The study provides strong evidence through targeted metabolomics and genetic models.
Source
ALOXE3 is a hepatic fasting-responsive lipoxygenase that enhances insulin sensitivity via hepatic PPARγ
Cassandra B. Higgins et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2018
other
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →